SCHEMBL10085281

SCHEMBL10085281

FC(F)(F)c1cncc(-c2ccc3nc(Nc4ccncc4)sc3c2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.59
PIK3CG P48736 9/20 0.47
NPC1 O15118 2/20 0.43
MAPT P10636 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
AKT1 P31749 2/20 0.43
DYRK1A Q13627 2/20 0.43
CSNK1D P48730 2/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
PRKCG P05129 1/20 0.43
LYN P07948 1/20 0.43
PRKACA P17612 1/20 0.43
RPS6KB1 P23443 1/20 0.43
FLT3 P36888 1/20 0.43
CLK2 P49760 1/20 0.43
IRAK1 P51617 1/20 0.43
PRKX P51817 1/20 0.43
NEK4 P51957 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10084975 0.88 PIK3CD (0.56) PIK3CDPIK3CGNPC1MAPTRAB9A
SCHEMBL10084867 0.85 PIK3CD (0.56) PIK3CDPIK3CGAKT1DYRK1ACSNK1D
SCHEMBL10084977 0.84 PIK3CD (0.55) PIK3CDPIK3CGNPC1MAPTRAB9A
SCHEMBL10084732 0.84 PIK3CD (0.56) PIK3CDPIK3CGAKT1DYRK1APIK3CA
SCHEMBL10084741 0.83 PIK3CD (0.56) PIK3CDPIK3CGAKT1DYRK1APIK3CA
SCHEMBL10081089 0.82 PIK3CG (0.64) PIK3CDPIK3CGNPC1MAPTRAB9A
SCHEMBL10084744 0.81 PIK3CD (0.56) PIK3CDPIK3CGAKT1DYRK1APIK3CA
SCHEMBL10084736 0.81 PIK3CD (0.58) PIK3CDPIK3CGAKT1PIK3CACYP3A4
SCHEMBL10085280 0.80 PIK3CD (0.57) PIK3CDPIK3CGAKT1DYRK1APIK3CA
SCHEMBL3710994 0.80 PIK3CD (0.74) PIK3CDPIK3CGDYRK1ACSNK1DPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8268999-B2 Tri-cyclic pyrazolopyridine kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-09-18 US disclosed
US-20120053187-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-01 US disclosed
WO-2010135014-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053187-A1 TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS PIK3CA, PIK3CD, PIK3CG PIK3CD 2/4885PIK3CG 3/4885NPC1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.